Cyclophosphamide
Angioimmunoblastic T-Cell Lymphoma
Explore 52 assets in Angioimmunoblastic T-Cell Lymphoma →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Shanghai Jiao Tong University School of Medicine
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07535762CT.gov Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07278856CT.gov Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | — | Recruiting | — | — | — |
NCT07055477CT.gov A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | — | Recruiting | — | — | — |
NCT07168317CT.gov Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL | — | Recruiting | — | — | — |
NCT07058103CT.gov Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL | — | Recruiting | — | — | — |
NCT06692452CT.gov Tazemetostat Plus CHOP in 1L T-cell Lymphoma | — | Withdrawn | — | — | — |
NCT06137144CT.gov AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. | — | Recruiting | — | — | — |
NCT06347653CT.gov Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL) | — | Recruiting | — | — | — |
NCT05572983CT.gov Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | — | Recruiting | — | — | — |
NCT05208853CT.gov An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | — | Unknown | — | — | — |
Show 20 more trialsShow fewer
NCT04803201CT.gov Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | — | Suspended | — | — | — |
NCT04795869CT.gov Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT03598998CT.gov Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03853044CT.gov Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | — | Unknown | — | — | — |
NCT03590574CT.gov Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | — | Terminated | — | — | — |
NCT03278782CT.gov Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | — | Active Not Recruiting | — | — | — |
NCT03113500CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03017820CT.gov A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | — | Recruiting | — | — | — |
NCT02533700CT.gov CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | — | Unknown | — | — | — |
NCT02223208CT.gov Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01466881CT.gov Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01336933CT.gov Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01198665CT.gov RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas | — | Completed | — | — | — |
NCT01129180CT.gov Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT00644189CT.gov Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00348985CT.gov PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT00103272CT.gov 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Terminated | — | — | — |
NCT00096005CT.gov Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Angioimmunoblastic T-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Shanghai Jiao Tong University School of Medicine | Approved | BB · 69 |
| Isocyclophosphamide | Shandong Provincial Hospital | P4 | BBB |
| Dexasone | Ou Bai, MD/PHD | P2 | BB |
| Azacitidine | National Cancer Institute (NCI) | P4 | BB |
| Prednisone | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Adriamycin | City of Hope Medical Center | P4 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BB |
| Etoposide | Eric Jacobsen, MD | P4 | BB |
| Romidepsin | The Lymphoma Academic Research Organisation | P3 | BB |
+42 more in the Angioimmunoblastic T-Cell Lymphoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Angioimmunoblastic T-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-angioimmunoblastic-t-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →